AbbVie Inc.'s Stock Analysis

AbbVie Announces Results from 2026 Annual Stockholders Meeting

AbbVie conducted its 2026 Annual Meeting of Stockholders on May 8, 2026. The meeting included a summary of the matters that were voted on by the stockholders, although specific details regarding the votes or outcomes were not provided.

May 12, 2026 17:01:51

AbbVie Annual Meeting of Stockholders Held on May 8, 2026

AbbVie conducted its 2026 Annual Meeting of Stockholders on May 8, 2026. The meeting covered various matters that were voted on by the stockholders, although specific details of the votes were not provided in the summary.

May 12, 2026 17:01:51

AbbVie Reports Q1 2026 Financial Results and Guidance Update

AbbVie reported first-quarter 2026 net revenues of $15.002 billion, reflecting a 12.4% increase on a reported basis and a 10.3% increase operationally. The immunology portfolio generated $7.290 billion in revenues, marking a 16.4% increase, driven by strong performances from Skyrizi and Rinvoq. The neuroscience portfolio also saw significant growth with $2.875 billion in revenues, up 26.0%. However, the oncology portfolio experienced a slight decline of 0.2%, while the aesthetics portfolio increased by 7.6%. The diluted earnings per share (EPS) was $0.39 on a GAAP basis, with adjusted diluted EPS at $2.65, which includes a negative impact of $0.41 per share from acquired IPR&D and milestones expenses.

AbbVie has raised its adjusted diluted EPS guidance for the full year 2026 from a range of $13.96 - $14.16 to $14.08 - $14.28, also accounting for the unfavorable impact of acquired IPR&D and milestones expenses. The company is advancing multiple programs in its pipeline, including submissions for FDA approvals for Skyrizi and Rinvoq in new indications. AbbVie also announced substantial investments in manufacturing facilities aimed at enhancing production capabilities for its immunology, neuroscience, and oncology products.

Apr 29, 2026 07:50:28

AbbVie Reports Earnings Impact from Acquired IPR&D Expenses

AbbVie anticipates that its GAAP and adjusted non-GAAP earnings for the first quarter of 2026 will reflect an unfavorable impact of $744 million related to acquired IPR&D and milestones expenses. This expense is expected to reduce both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share by $0.41. The company has provided adjusted diluted earnings per share guidance for the first quarter of 2026 in the range of $2.56 to $2.60, which includes this expense.

For the full year 2026, AbbVie has set an adjusted diluted earnings per share guidance range of $13.96 to $14.16, accounting for the first quarter expenses. The company has previously indicated that the guidance excludes any further IPR&D and milestones expenses that may arise later in the year, as these expenses cannot be reliably predicted. Final results for the first quarter are still subject to review and may differ from the preliminary estimates provided.

Apr 03, 2026 16:05:55

AbbVie Completes $5.25 Billion Notes Offering for Various Maturities

AbbVie Inc. has successfully completed a public offering totaling $5.25 billion in senior notes, which includes $750 million in floating rate notes and $4.5 billion in fixed rate notes across multiple maturities ranging from 2028 to 2066. The offering, registered under the Securities Act, is structured in accordance with AbbVie’s existing debt obligations and is governed by a supplemental indenture. The notes are unsecured and will rank equally with AbbVie's other unsecured debt.

The notes will mature on various dates, with the floating rate notes and 2028 fixed rate notes maturing on March 3, 2028, while other fixed rate notes will mature on March 15 of their respective years. AbbVie retains the option to redeem certain notes before their maturity dates at specified prices. The indenture includes standard covenants that limit AbbVie's ability to incur additional liens or merge with other entities, which may impact its financial flexibility.

Mar 04, 2026 16:59:47

AbbVie Announces $7.95 Billion Senior Notes Offering

AbbVie Inc. has entered into an underwriting agreement to issue and sell various senior notes totaling approximately $7.95 billion. This includes $750 million in senior floating rate notes due 2028, and several other series of senior notes with maturities ranging from 2028 to 2066, with interest rates from 3.775% to 5.650%. The offering has been registered under the Securities Act and is expected to close on March 4, 2026, subject to customary conditions.

The net proceeds from this offering will primarily be used to repay amounts outstanding under AbbVie's $4.0 billion 364-Day delayed draw term loan facility, which is maturing in May 2026, as well as for general corporate purposes, including potential debt repayment or repurchase. The underwriting agreement includes standard representations and covenants by AbbVie, along with indemnification provisions for the underwriters. Additional details regarding the terms of the notes can be found in the accompanying prospectus supplements.

Feb 26, 2026 17:14:40

AbbVie Announces $7.95 Billion Senior Notes Offering

AbbVie Inc. has entered into an underwriting agreement to issue and sell $7.95 billion in senior notes, including various series of notes due between 2028 and 2066. The notes consist of senior floating rate notes and fixed-rate senior notes with varying interest rates, and the offering has been registered under the Securities Act of 1933. The public pricing for the notes ranges from 99.714% to 100.000% of the principal amount, depending on the specific series.

The net proceeds from this offering are intended to be used to repay outstanding amounts under a $4.0 billion term loan facility that matures in May 2026, as well as for general corporate purposes, which may include debt repayment or repurchase. The closing of the sale is expected to occur on March 4, 2026, subject to customary closing conditions. Additional details regarding the offering and terms of the notes are available in the preliminary and final prospectus supplements filed with the SEC.

Feb 26, 2026 17:14:40

AbbVie Reports Q4 and Full-Year 2025 Financial Results

AbbVie reported full-year 2025 net revenues of $61.160 billion, marking an 8.6% increase compared to the previous year. The company experienced growth in its immunology and neuroscience portfolios, with global net revenues of $30.406 billion and $10.767 billion, respectively. However, revenues from the aesthetics portfolio decreased by 6.1%. For the fourth quarter, AbbVie achieved net revenues of $16.618 billion, a 10.0% increase, with diluted EPS of $1.02 on a GAAP basis and adjusted diluted EPS of $2.71, which included an unfavorable impact from acquired IPR&D and milestones expense.

For 2026, AbbVie provided adjusted diluted EPS guidance of $14.37 to $14.57, excluding impacts from acquired IPR&D and milestones. The company also announced several recent developments, including a voluntary agreement with the Trump administration to enhance access to medications, submissions for new drug indications, and the acquisition of a manufacturing facility to support future product needs. These strategic moves aim to bolster AbbVie's growth and innovation in the pharmaceutical market.

Feb 04, 2026 07:54:33

AbbVie Reports Q4 2025 Earnings Guidance and Expenses

AbbVie anticipates that its fourth quarter 2025 GAAP and adjusted non-GAAP earnings will include an acquired IPR&D and milestones expense of $1.3 billion before tax, which is expected to negatively affect diluted earnings per share by $0.71. The full-year adjusted diluted earnings per share guidance for 2025 is projected to range from $9.90 to $9.94, while the fourth quarter adjusted diluted earnings per share guidance is estimated between $2.61 and $2.65, factoring in this expense.

The company noted that the results for the quarter ending December 31, 2025, are not finalized and may differ from the preliminary estimates provided. AbbVie does not predict future acquired IPR&D and milestones expenses due to uncertainties surrounding the timing and occurrence of related transactions. Additional information regarding risks and uncertainties that could influence AbbVie's operations is detailed in their filings with the Securities and Exchange Commission.

Jan 07, 2026 16:08:59

AbbVie Reports Third-Quarter 2025 Financial Results and Dividend Increase

AbbVie Inc. reported third-quarter 2025 financial results, with diluted earnings per share (EPS) of $0.10 on a GAAP basis, representing an 88.6% decrease, and adjusted diluted EPS of $1.86, a decrease of 38.0%. Net revenues for the quarter reached $15.776 billion, up 9.1% from the previous year, driven by strong performance in the immunology and neuroscience portfolios, which saw increases of 11.9% and 20.2%, respectively. However, revenues from the oncology and aesthetics portfolios experienced slight declines. The company has raised its adjusted diluted EPS guidance for the full year to a range of $10.61 to $10.65, accounting for an unfavorable impact of $2.05 per share related to acquired IPR&D and milestones expenses incurred year-to-date.

Additionally, AbbVie announced a 5.5% increase in its quarterly cash dividend, raising it from $1.64 to $1.73 per share, effective February 2026. This reflects AbbVie's commitment to returning cash to shareholders, as the company has increased its dividend by over 330% since its inception in 2013. The company is also advancing its pipeline with several new drug applications and clinical trial results that may further enhance its market position.

Oct 31, 2025 07:51:43